Torii Pharmaceutical Co., Ltd.
Torii Pharmaceutical Co., Ltd. Fundamental Analysis
Torii Pharmaceutical Co., Ltd. (4551.T) shows weak financial fundamentals with a PE ratio of 43.49, profit margin of 8.47%, and ROE of 3.37%. The company generates $48.5B in annual revenue with strong year-over-year growth of 10.59%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4551.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4551.T struggles to generate sufficient returns from assets.
Valuation Score
Weak4551.T trades at a premium to fair value.
Growth Score
Excellent4551.T delivers strong and consistent growth momentum.
Financial Health Score
Excellent4551.T maintains a strong and stable balance sheet.
Profitability Score
Weak4551.T struggles to sustain strong margins.
Key Financial Metrics
Is 4551.T Expensive or Cheap?
P/E Ratio
4551.T trades at 43.49 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 4551.T's PEG of 14.83 indicates potential overvaluation.
Price to Book
The market values Torii Pharmaceutical Co., Ltd. at 1.46 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 31.88 times EBITDA. This signals the market has high growth expectations.
How Well Does 4551.T Make Money?
Net Profit Margin
For every $100 in sales, Torii Pharmaceutical Co., Ltd. keeps $8.47 as profit after all expenses.
Operating Margin
Core operations generate 10.91 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.37 in profit for every $100 of shareholder equity.
ROA
Torii Pharmaceutical Co., Ltd. generates $2.90 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Torii Pharmaceutical Co., Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Torii Pharmaceutical Co., Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
4551.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.49
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
14.83
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.18
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How 4551.T Stacks Against Its Sector Peers
| Metric | 4551.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.49 | 29.77 | Worse (Expensive) |
| ROE | 3.37% | 682.00% | Weak |
| Net Margin | 8.47% | -45016.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.42 | Strong (Low Leverage) |
| Current Ratio | 5.18 | 4.49 | Strong Liquidity |
| ROA | 2.90% | -16121.00% (disorted) | Weak |
4551.T outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Torii Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
40.33%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-81.60%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-91.45%
Industry Style: Defensive, Growth, Innovation
Declining